Antohe et al. recently investigated, in a small cohort of AML patients, the expression of HLA-DR, several molecules involved in HLA-II antigen presentation (HLA-DM, CD74 and CLIP) and some checkpoint ligands, finding high levels of HLA-DM and CD74 in all patients, but low HLA-DR expression in only 23% of them. This evidence concerns the gene HLA-DMA and acute myeloid leukemia.